Premier Alternatives

Alessa Therapeutics

San Carlos, CA · Founded 2018 · Privately Held (backing)

Developer of a drug delivery implantable system designed to treat patients with prostate cancer. Alessa Therapeutics is based in San Carlos, CA and was founded in 2018. It was valued at $49 million at its later-stage round in Apr 2025, the last priced event on record. It has raised $31.6 million across 3 recorded rounds; the latest was a $25.4 million early-stage round in Apr 2025.

PMV mark · valuation
$49.0M
Oct 2026
Priced at
its later-stage round
Apr 2025
Total raised
$31.6M
Last round
Early Stage VC
Apr 2025

Alessa Therapeutics key facts

as of Oct 2026
  • Developer of a drug delivery implantable system designed to treat patients with prostate cancer.
  • Alessa Therapeutics is valued at approximately $49.0M as of Oct 2026, set at its later-stage round, Apr 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $31.6M across 3 recorded rounds; the latest was Early Stage VC ($25.4M) in Apr 2025.
  • Notable investors include National Institutes of Health, Mission BioCapital, University of California San Francisco Foundation, Cure Ventures, Johnson & Johnson — 10 tracked in total.
  • Alessa Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently May 2025 ($25.4M sold to 14 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$49.0M

Valued at $49.0M at its later-stage round, Apr 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Alessa Therapeutics with a free account
  • ·Watch Alessa Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Alessa Therapeutics funding rounds

3 rounds
Apr 2025Early Stage VC$25.4MSEC filing▮
Dec 2019Seed Round$3.3MSEC filing▮
Mar 2019Seed Round$3.0MSEC filing▮
Full funding history →

Alessa Therapeutics valuation

Alessa Therapeutics was valued at $49 million at its later-stage round in Apr 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Alessa Therapeutics raised?

Alessa Therapeutics has raised $31.6 million across 3 recorded rounds since 2019. The largest was a $3.3 million seed round in Dec 2019; the most recent was a $25.4 million early-stage round in Apr 2025.

Alessa Therapeutics has filed 3 Form Ds with the SEC since 2019, most recently in May 2025 ($25.4 million sold to 14 investors).

Alessa Therapeutics investors

10 investors are on record for Alessa Therapeutics, including National Institutes of Health, Mission BioCapital, University of California San Francisco Foundation and Cure Ventures. The early-stage round in Apr 2025 drew 14 investors.

About Alessa Therapeutics

Developer of a drug delivery implantable system designed to treat patients with prostate cancer. The company's system helps to administer anti-androgen drugs to the tumor in the prostate through a sustained and localized system without systemic exposure, enabling patients to have localized treatments for solid organ disease.

Sector
Healthcare
HQ
San Carlos, CA, United States
Founded
2018
Employees
13
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.